Simeprevir (Olysio®)

Assessment Status Rapid Review Complete
Drug Simeprevir
Brand Olysio®
Indication In combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients as part of a triple therapy regimen (co-administered with PegInterferon + Ribavirin) to treat hepatitis C virus (HCV) Genotypes 1 and 4 who are treatment naïve or have previously been treated.
Assessment Process
Rapid review commissioned 27/05/2014
Rapid review completed 11/07/2014
Rapid review outcome Full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin.